



Therapeutic Products Directorate: TPD-Web

[Copyright Requests](#) |[Needed Downloads](#)[Health Products and Food Branch Home](#)[Health Canada Home](#)[Home](#)[What's New](#)[About Us](#)[Related Links](#)[Subscribe](#)[SiteMap](#)[Medical Devices](#)[Drugs](#)

- [Acts & Regulations](#)
- [Application / Submission Information](#)
- [Drug Product Database](#)
- [Drug Submission Performance Reports](#)
- [Fees](#)
- [Notice of Compliance Listings](#)
- [Patent Register](#)
- [Projects](#)
- [Reports](#)

[Adverse Reaction Information](#)[Advisories and Warnings](#)[Regulatory Requirements for Advertising](#)[Special Access Programme](#)[Activities](#)[Communications](#)

Contact
[Vince Iacobucci](#)

Graham Spry Building
250 Lanark Avenue
A.L. 2005D
Ottawa, Ontario
K1A 0K9

04-124728-284

Provincial and Territorial Deputy Ministers of Health
Provincial and Territorial Drug Program Managers
Deans of Pharmacy
Registrars of Provincial Medical and Pharmacy Associations
Industry and Consumer Associations
Regulatory and Health Professional Associations
Other Interested Parties

Dear Sir/Madam:

Re: *Food and Drug Regulations* - Project # 1448 - Schedule F

This letter is to provide you with an opportunity to comment on the proposed addition of **Danofloxacin and its salts** to Part I of Schedule F to the *Food and Drug Regulations* to the *Food and Drugs Act*.

Schedule F is a list of medicinal ingredients, the sale of which is controlled under sections C.01.041 to C.01.049 of the *Food and Drug Regulations*. Part I of Schedule F lists ingredients that require a prescription for human use and for veterinary use. Part II of Schedule F lists ingredients that require a prescription for human use, but do not require a prescription for veterinary use if so labelled or if in a form unsuitable for human use.

The Drug Schedule Status Committee determined the necessity for prescription status for the medicinal ingredient in this proposed amendment on the basis of established and publicly available criteria. These criteria include, but are not limited to, concerns related to toxicity, pharmacological properties and therapeutic applications.

Danofloxacin and its salts is a 'third-generation' fluoroquinolone antibiotic. Fluoroquinolones are a group of broad-spectrum antibiotics that are used to treat bacterial infections by preventing bacterial growth.

Danofloxacin is used in veterinary medicine as the mesylate salt for the treatment of respiratory diseases in cattle, swine, and chickens. Danofloxacin is not intended for use in dairy cattle producing milk for human consumption and not in laying hens. Danofloxacin should be used only under the supervision of a veterinarian since indiscriminate use of this drug in animals could result in antimicrobial resistance development in other fluoroquinolones of importance in human medicine.

The degree of regulatory control afforded by Schedule F (prescription drug) status coincides with the risk factors associated with this medicinal ingredient. Oversight by a practitioner is necessary to ensure that adequate risk/benefit information is available before the drug containing the medicinal ingredient is administered and that the drug therapy is properly monitored.

This document is also available in PDF format
[\[project_projet_1448_e.pdf\]](#)

Pages: 03, Size: 21 K, Date: 2005-05-11

Alternatives

Any alternatives to the degree of regulatory control recommended in this amendment would need to be established through additional scientific information and clinical experience.

No other alternatives were considered.

Benefits and Costs

The amendment will impact on the public. Prescription access to drug products containing this medicinal ingredient would benefit Canadians by decreasing the opportunities for improper use and by ensuring the guidance and care of a practitioner.

Compliance and Enforcement

This amendment will not alter existing compliance mechanisms under the provisions of the *Food and Drugs Act* and its *Regulations* enforced by the Health Products and Food Branch Inspectorate.

Consultation

The manufacturer affected by this proposed amendment was made aware of the intent to recommend this medicinal ingredient for inclusion on Schedule F during the review of the drug submission.

The process for this consultation with stakeholders is described in the Memorandum of Understanding (MOU) to streamline regulatory amendments to Schedule F, which came into effect on February 22, 2005. The MOU is posted on the Health Canada website at http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/mou_schedule-f_e.html.

This letter is being sent by email to stakeholders and is also being posted on the Therapeutic Products Directorate (TPD) website at http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/index_drugs_regulations_e.html and the "Consulting Canadians" website at <http://www.consultingcanadians.gc.ca>.

Any comments regarding this proposed amendment should be addressed to Vince Iacobucci, Policy Division, Policy Bureau, Therapeutic Products Directorate, 1600 Scott Street, Holland Cross, Tower 'B', 2nd Floor, Address Locator 3102C5, Ottawa, Ontario, K1A 1B6, by facsimile at 613-941-6458 or by email to vince_iacobucci@hc-sc.gc.ca within **75** days following the date of posting of this letter on the TPD website.

Final Approval

In accordance with the MOU process, it is anticipated that this amendment will proceed directly from this consultation to final publication in the *Canada Gazette*, Part II, approximately 6 to 8 months from the date of posting of this letter on the TPD website. The amendment will come into force on the date of registration.

Yours sincerely,

Original Signed by

Diane Gorman
Assistant Deputy Minister

